Expanding the Database and Business Platform Through Acquisitions
First written in FY2020. 21 of 22 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Assets at the end of the fiscal year under review increased by ¥15,517 million from the end of the previous fiscal year to ¥158,538 million. This was mainly due to increases of ¥7,005 million in property, plant and equipment, ¥4,155 million in goodwill, and ¥3,949 million in trade and other receivables.」
Goodwill increased by ¥4,155 million in connection with business combinations and other transactions. Expansion of the business platform through acquisitions continued. - FY2026-H1AdvancedAnnual report
「This was mainly due to a ¥3,661 million decrease in trade and other receivables, together with increases of ¥3,687 million in cash and cash equivalents, ¥3,200 million in property, plant and equipment and ¥2,775 million in contract assets, as well as a ¥3,404 million increase in goodwill associated with the acquisition of newly consolidated subsidiaries and other transactions.」
Goodwill, primarily in the health big data business, increased by ¥3,404 million in connection with the acquisition of newly consolidated subsidiaries and other transactions. Expansion of the business platform through acquisitions continued during the interim period. - FY2025AdvancedAnnual report
「Acquisitions through business combinations 3,595」
During the fiscal year under review, acquisitions through business combinations increased goodwill, primarily in the health big data business, by ¥3,595 million. Expansion of the business platform through acquisitions and business combinations continued. - FY2025-H1AdvancedAnnual report
「During the interim consolidated accounting period, goodwill in the health big data segment increased by ¥2,065 million following business combinations and other transactions that were immaterial individually and in aggregate.」
Business combinations were also completed during the interim period, increasing goodwill in the health big data segment by ¥2,065 million. Acquisitions and expansion of the business platform, primarily in the medical data business, continued. - FY2024AdvancedAnnual report
「During the fiscal year under review, the Company made 株式会社キャンサースキャン a subsidiary. Through 株式会社キャンサースキャン's strong customer base among local governments, the Company will deploy the services and solutions it has developed through transactions with health insurance societies. It will also provide the Company's customers, including health insurance societies and corporations, with solutions such as lifestyle-related disease treatment programs developed by applying 株式会社キャンサースキャン's strength in behavior-change expertise, thereby accelerating further expansion of the Group's business scale in the insurer and consumer area.」
By making 株式会社キャンサースキャン a subsidiary, the Company specified its policy of incorporating its local-government customer base and behavior-change expertise into its existing business serving insurers and consumers. - FY2024-Q3AdvancedAnnual report
「During the cumulative third quarter, goodwill in the health big data segment increased by ¥5,555 million following a business combination that was immaterial individually and in aggregate. / At a Board of Directors meeting held on 28 December 2023, the Company resolved to acquire the shares of 株式会社キャンサースキャン and make it a subsidiary, and completed the acquisition of all shares on 26 January 2024.」
Business combinations continued in the health big data area, increasing goodwill by ¥5,555 million. In addition, the Company completed the acquisition of all shares of 株式会社キャンサースキャン on 26 January 2024, expanding its business platform in the insurer and consumer area. - FY2024-Q2AdvancedAnnual report
「During the cumulative second quarter, goodwill in the health big data segment increased by ¥2,735 million following a business combination that was immaterial individually and in aggregate.」
A business combination was completed during the cumulative quarter, increasing goodwill in the health big data segment by ¥2,735 million. Acquisitions continued to expand the platform for the medical data business. - FY2024-Q1AdvancedAnnual report
「During the cumulative first quarter, goodwill in the health big data segment increased by ¥1,642 million following a business combination that was immaterial individually and in aggregate.」
A business combination was completed during the first quarter, increasing goodwill in the health big data segment by ¥1,642 million. Acquisitions continued to expand the platform for the medical data business. - FY2023AdvancedAnnual report
「The Company decided to carry out an absorption-type merger because it expects further business strengthening through the integration of its expertise in data security and privacy protection, anonymized data management, including data cleansing and standardization, and its ability to propose ways of using data, including analytics and data science.」
For リアルワールドデータ株式会社, the Company decided on an absorption-type merger to integrate its anonymized database business into the Company. The disclosure specifies business strengthening through the integration of data security, anonymization and standardization, analytics, and data science functions. - FY2023-Q3AdvancedAnnual report
「On 29 July 2022, the Company acquired the shares of リアルワールドデータ株式会社 and made it a subsidiary. Including other subsidiary acquisitions and similar transactions, the number of subsidiaries increased by a net 6 during the cumulative quarter.」
In addition to making リアルワールドデータ株式会社 a subsidiary, the number of subsidiaries, including other acquisitions, increased by a net 6 during the cumulative quarter. Expenditures for the acquisition of subsidiary shares in connection with business combinations were ¥19,213 million, and goodwill in the health big data segment increased by ¥19,832 million. - FY2023-Q2AdvancedAnnual report
「During the six months ended the second quarter, the company substantially expanded its medical institution-sourced data by making Real World Data Co., Ltd. and other companies subsidiaries, and began efforts to provide services in new areas such as clinical trials.」
In addition to リアルワールドデータ株式会社, the Company made other companies subsidiaries, expanding its medical institution-derived data and business platform. Expenditures for the acquisition of shares in subsidiaries resulting in a change in the scope of consolidation were ¥19,202 million. - FY2023-Q1AdvancedAnnual report
「During the cumulative first quarter, goodwill in the health big data segment increased by ¥3,157 million following a business combination that was immaterial individually and in aggregate.」
The Company completed a business combination in the health big data area during the quarter, increasing goodwill by ¥3,157 million. It also disclosed, as a subsequent event, that it completed the acquisition of all shares of リアルワールドデータ株式会社 on 29 July 2022. - FY2022AdvancedAnnual report
「During the fiscal year under review, business combinations were carried out in the health big data and dispensing-pharmacy support segments. On a combined basis for these acquisitions, the fair value of the consideration paid was ¥5,003 million and goodwill was ¥5,461 million.」
Business combinations were completed in the health big data and dispensing-pharmacy support businesses, with cash consideration of ¥5,003 million and goodwill of ¥5,461 million recognized. - FY2022-Q3AdvancedAnnual report
「During the cumulative third quarter, business combinations were carried out in the health big data and dispensing-pharmacy support segments. On a combined basis for these acquisitions, the fair value of the consideration paid was ¥4,948 million and goodwill was ¥5,419 million.」
The disclosure states that business combinations were completed during the cumulative quarter in both the health big data and dispensing-pharmacy support segments, with acquisition consideration of ¥4,948 million and goodwill of ¥5,419 million recognized. - FY2022-Q2AdvancedAnnual report
「During the cumulative second quarter, goodwill increased by ¥2,809 million in the health big data segment and by ¥1,395 million in the dispensing-pharmacy support segment following business combinations that were immaterial individually and in aggregate.」
Business combinations increased goodwill in the health big data segment by ¥2,809 million and in the dispensing-pharmacy support segment by ¥1,395 million. In addition to the continuing impact on dispensing-pharmacy support from the previous quarter, the disclosure reports the impact of business combinations in the health big data area. - FY2022-Q1AdvancedAnnual report
「During the cumulative first quarter, goodwill in the dispensing-pharmacy support segment increased by ¥1,395 million following a business combination that was immaterial individually and in aggregate.」
The Company completed a business combination during the quarter, increasing goodwill in the dispensing-pharmacy support segment by ¥1,395 million. This indicates that the business platform in the dispensing-pharmacy support area was further expanded through business combinations. - FY2021-Q3AdvancedAnnual report
「The Group's condensed interim consolidated income statement includes revenue of ¥128 million and interim profit of ¥43 million generated by データインデックス株式会社 since the acquisition date.」
The disclosure quantifies for the first time データインデックス株式会社's contribution to results after it became a subsidiary. Revenue of ¥128 million and interim profit of ¥43 million generated since the acquisition date are included in the consolidated results. - FY2021-Q2AdvancedAnnual report
「Through the share exchange, the Company will make データインデックス株式会社 a subsidiary, further strengthening its pharmaceutical information database in both quality and scale and accelerating the consolidation of diverse data from Japan's healthcare industry. In addition, by leveraging データインデックス株式会社's network of approximately 45,000 medical institutions, dispensing pharmacies and other organizations nationwide, the Company will expand the network through which the medical big data it has consolidated is returned to and circulated throughout society.」
The Company made データインデックス株式会社 a wholly owned subsidiary through a share exchange on 2 November 2020. The disclosure describes specific initiatives to strengthen the pharmaceutical information database, leverage the network of approximately 45,000 medical institutions and dispensing pharmacies nationwide, and pursue joint database development and cost synergies. - FY2021-Q1AdvancedAnnual report
「On 1 April 2020, the Company acquired the shares of エヌエスパートナーズ株式会社 and made it a subsidiary.」
The Company acquired 100% of the voting equity interest in エヌエスパートナーズ株式会社 and made it a subsidiary, with the aim of further expanding services for medical institutions and creating new value. The consideration paid was ¥4,450 million. - FY2020First statedAnnual report
「The objective is to expand the database lineup and create new value.」
In February 2020, the Company acquired ミーカンパニー株式会社 to expand its databases of medical institutions, pharmacies and care services. It positions acquisitions as a means of implementing its growth strategy.